+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients



Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients



Journal of Clinical Oncology 5(6): 906-911



Fifty patients with clinical stage II nonseminomatous germ cell tumor of the testis (NSGCTT) were treated with primary chemotherapy followed by a retroperitoneal lymph node dissection (RPLND) in selected patients. The study population included 34 patients with retroperitoneal masses and elevated levels of serum biomarkers (alpha-fetoprotein [AFP] and beta-human chorionic gonadotropin [BHCG] ), five with needle aspiration biopsy-proven retroperitoneal metastases but normal levels of biomarkers, and 11 in whom there were rising levels of serum biomarkers but no radiographic evidence of retroperitoneal metastases. Forty-eight patients (96%) achieved a complete response (CR), with a mean disease-free survival of 132 weeks (range, 55 to 273 weeks). Two patients developed recurrent disease. One died and one achieved a second CR with further therapy (48 + weeks). Postchemotherapy RPLND was required in 11 patients (22%). Patients with embryonal carcinoma had a lower frequency of RPLND (8%) than patients with teratomatous elements in their primary tumor [36%, P = .014]. To reduce the frequency of double therapy (surgery +/- chemotherapy), we propose individualized therapy. Patients presenting with clinical stage II embryonal carcinoma of the testis should receive primary chemotherapy. Patients with clinical stage II NSGCTT and teratomatous elements in their primary tumor continue to require an RPLND. Those patients with intermediate volume disease (greater than 2 cm less than or equal to 5 cm in maximum diameter) may be treated with an RPLND only. Patients with higher volume teratomatous elements (greater than 5 cm less than or equal to 10 cm in maximum diameter) are likely to require the combination of chemotherapy and surgery.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 041064633

Download citation: RISBibTeXText

PMID: 2438389

DOI: 10.1200/jco.1987.5.6.906


Related references

Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. Journal of Urology 151(1): 72-7; Discussion 77-8, 1994

Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testis tumors. Urologic Clinics of North America 20(1): 93-109, 1993

No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. Journal of Urology 131(4): 677-680, 1984

Orchiectomy alone for clinical stage I nonseminomatous germ cell tumors of the testis (NSGCTT): a minimum follow-up period of 5 years. Tumori 80(5): 362-364, 1994

Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. Journal of Urology 155(4): 1296-1298, 1996

Rplnd or Primary Chemotherapy in Clinical Stage Iia/B Nonseminomatous Germ Cell Tumors?. European Urology 37(5): 582-594, 2000

Surveillance Alone for Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Preliminary Results. The Journal of Urology 131(3): 491-493, 1984

Surveillance alone for patients with clinical stage 1 nonseminomatous germ cell tumors of the testis preliminary results. Journal of Urology 131(3): 491-493, 1984

Stage I nonseminomatous germ cell tumors of the testis: radiologic follow-up after orchidectomy. Radiology 164(3): 671-674, 1987

Management of patients with clinical stage I or II nonseminomatous germ cell tumors of the testis. Evolving therapeutic options. Archives of Surgery 122(12): 1443-1445, 1987

Adjuvant chemotherapy in resected stage-II nonseminomatous germ cell tumors of testis. In which cases is it necessary?. European Urology 10(3): 151-158, 1984

Adjuvant chemotherapy with vinblastine and bleomycin in stage B nonseminomatous germ cell tumors of the testis. Journal of Urology 128(4): 712-714, 1982

Management of patients with clinical stage i and ii nonseminomatous germ cell tumors nsgct of the testis evolving therapeutic options. Journal of Urology 139(4 PART 2): 205A, 1988

Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. Journal of Urology 179(1): 163-166, 2007

Chemotherapy in stage II nonseminomatous germ cell tumors of the testis: The institut Gustave roussy experience. Urologic Oncology 1(5): 175-183, 1995